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http://dx.doi.org/10.1016/j.ccell.2014.10.021SUMMARYDisrupted differentiation during development can lead to oncogenesis, but the underlying mechanisms
remain poorly understood. Here we identify BCL6, a transcriptional repressor and lymphoma oncoprotein,
as a pivotal factor required for neurogenesis and tumor suppression of medulloblastoma (MB). BCL6 is
necessary for and capable of preventing the development of GNP-derived MB in mice, and can block the
growth of humanMBcells in vitro. BCL6 neurogenic and oncosuppressor effects rely on direct transcriptional
repression of Gli1 and Gli2 effectors of the SHH pathway, through recruitment of BCOR corepressor and
SIRT1 deacetylase. Our findings identify the BCL6/BCOR/SIRT1 complex as a potent repressor of the
SHH pathway in normal and oncogenic neural development, with direct diagnostic and/or therapeutic rele-
vance for SHH MB.INTRODUCTION
During embryonic development, the balance between prolifera-
tion and differentiation, and the subsequent emergence of
cellular diversity, depend on a delicate interplay between
intrinsic and extrinsic cues. The same morphogenic pathways
are often deregulated during oncogenesis (Taipale and Beachy,
2001), and indeed many tumors are thought to result from aber-
rant differentiation events, although in most cases the underlying
mechanisms remain poorly understood. One striking example of
the tight link between morphogenesis and oncogenesis is me-
dulloblastoma (MB), the most prevalent malignant brain tumor
in children.MB are thought to be caused at least in part by dereg-
ulation of pathways normally acting during brain development,
such as WNT and Sonic Hedgehog (SHH) pathways (Parsons
et al., 2011; Roussel and Hatten, 2011). Importantly the pathwaySignificance
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relevant for tumors that are thought to be of developmental or
coprotein, acts as a key neurogenesis factor during normal ce
medulloblastoma. Remarkably, both effects rely on the sam
Hedgehog signaling effectors Gli1 and Gli2 through the recr
data identify the BCL6/BCOR/SIRT1 complex as an important
SHH medulloblastoma.
Caat stake has a direct impact on the clinical features of the tumor,
leading to the classification of MB into four major subgroups,
with pathological features associated with specific molecular
pathways (Kool et al., 2014; Northcott et al., 2012a, 2012b; Ol-
son, 2014; Thompson et al., 2006). The SHH subtype accounts
for approximately 25% of MB. SHH MB are caused mainly by
aberrant gain of function of the SHH pathway (Northcott et al.,
2012a). Indeed human SHH MB tumors are frequently associ-
ated with disruptive mutations of genes encoding negative
regulators of SHH signaling, such as PTCH1 or SUFU, or ampli-
fication of genes encoding SHH effectors or SHH target genes,
such as GLI2 or MYCN (Gilbertson and Ellison, 2008; Northcott
et al., 2012a).MB are typically located in the cerebellum, inwhich
granule neuron precursors (GNP) were found to constitute the
main cells of origin of SHH MB in the mouse (Schu¨ller et al.,
2008; Yang et al., 2008).elopmental pathways and oncogenesis. This is particularly
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BCL6 Suppresses Sonic Hedgehog MedulloblastomaThe SHH pathway plays a crucial role in the normal develop-
ment of the cerebellum, in particular in GNP (Fuccillo et al.,
2006). In mice, SHH is normally secreted by Purkinje neurons
in the developing cerebellum, where it promotes the expansion
andmaintenance of GNP through activation of Gli1 andGli2 tran-
scription factors, the main positive effectors of the SHH pathway
(Corrales et al., 2006; Fuccillo et al., 2006). Interestingly, other
factors involved in GNP development have been linked to MB
oncogenesis, most strikingly the MATH1/Atoh1 transcription
factor that is required for the specification and proliferation of
GNP (Ben-Arie et al., 1997), while its disruption in the mouse re-
sults in a block of SHH MB development, mostly through tran-
scriptional control of Gli genes (Dahmane and Ruiz i Altaba,
1999; Flora et al., 2009). Collectively these data provide a direct
link between genes that promote specification and expansion of
GNP and SHH MB oncogenesis. Conversely, the proneurogenic
factors that promote the neurogenic conversion of GNP into
granule neurons during normal in vivo development could pro-
vide leads toward MB oncosuppression, but their nature and
mechanisms of action remain essentially unknown. BMP cues
have been reported to be able to increase GNP neurogenesis
in vitro, while inhibiting the oncogenic growth of humanMB cells,
but their requirement in any of these processes has not been
tested (Grimmer and Weiss, 2008; Zhao et al., 2008). Similarly,
proneural genes such as Neurod1 and Mash1 have been impli-
cated in granule neuron differentiation (Alvarez-Rodrı´guez and
Pons, 2009; Cho and Tsai, 2006), but their potential involvement
in MB remains unexplored.
BCL6 is a transcriptional repressor involved in B cell develop-
ment and oncogenesis (Basso and Dalla-Favera, 2012; Chang
et al., 1996; Duy et al., 2011; Hurtz et al., 2011; Ye et al., 1993,
1997), but recently has been identified also as a proneurogenic
factor in the developing cerebral cortex (Tiberi et al., 2012).
Here, we explore the role of BCL6 during cerebellar neurogene-
sis and its involvement in MB oncogenesis.
RESULTS
BCL6 Is Expressed in GNP during Cerebellar
Neurogenesis
To test the effect of BCL6 in neural cell populations, we surveyed
its expression in the developing brain and found high levels of
expression in the postnatal cerebellum. BCL6 was strongly ex-
pressed in the external granular layer (EGL), which contains
GNP aswell as differentiating granule neurons, and in the internal
granular layer, containing postmigratory granule neurons (Fig-
ure 1A). Costainings for BCL6 and Ki67 (marker of proliferating
GNP) or NeuN (marker of postmitotic granule neurons) revealed
a partially overlapping pattern, with BCL6 expressed among
Ki67+ GNP (Figure 1B and Figure S1A available online) and
early-born neurons in the EGL, as well as in differentiated
NeuN+ granule neurons in the internal granule layer (IGL) (Figures
1B and 1C). Calbindin+ Purkinje cells did not express BCL6 (Fig-
ure S1B). Importantly, the specificity of BCL6 immunostaining
was confirmed in each case using Bcl6 knockout (KO) mice,
which revealed no immunostaining (Figures 1D and S1C). These
data indicate that BCL6 is expressed in GNP during their transi-
tion to a neuronal fate, consistent with a role during neurogenesis
as in the cerebral cortex (Tiberi et al., 2012).798 Cancer Cell 26, 797–812, December 8, 2014 ª2014 Elsevier Inc.BCL6 Is Required for Proper GNP Neuronal
Differentiation
We then examined Bcl6 KO mice (Ye et al., 1997) and found
decreased cerebellar size and weight at P21 (Figure S1D), sug-
gesting a disruption of GNP proliferation, survival, and/or differ-
entiation. The proliferation patterns of GNP were analyzed using
pH3 and Ki67 stainings and did not reveal significant alteration in
Bcl6 KO mice at the time of neurogenesis (Figures S1A, S1C,
S1E, and S1F). We then examined the number of NeuN+ cells
specifically in the EGL at P7, and we found a decrease in the
newly born neurons in KO compared to wild-type (WT) (Figures
1C–1E) as well as a decrease in NeuN+ IGL area (Figure 1F).
Overall, these data strongly suggest a defect in the generation
of granule neurons in the Bcl6 KO mice.
We next performed EdU pulse-chase experiments combined
with Ki67 staining and found a marked reduction of cell-cycle
exit at P7 in the cerebellum of Bcl6 KO mice, further confirming
defective neurogenesis from GNP to postmitotic neurons (Fig-
ures 1G and 1H). Apoptosis, as determined by the number of
cleaved caspase 3+ cells, was increased in Bcl6 KO mice at
P7 (Figures S1G and S1H), suggesting aberrant neuronal spec-
ification. We then determined whether BCL6 was able to trigger
GNP neurogenesis using a gain-of-function approach on ex vivo
cultures of GNP. BCL6 overexpression resulted in a potent
neurogenic effect, characterized by an increase in the number
of NeuN+ neurons generated after 72 hr (Figure S1I). Fluores-
cence-activated cell sorting (FACS) analysis using the anti-
cleaved caspase 3 antibody revealed no difference in the per-
centage of apoptotic cells within the different conditions
(percentage cleaved caspase 3+ cells: Ctr, 3.30 ± 0.43; BCL6,
3.16 ± 0.68; n = 8; Figures S1J and S1K). Altogether these
data indicate that BCL6 is required in vivo for the proper differ-
entiation of GNP and it is able to trigger GNP neurogenesis
in vitro.
BCL6 Acts as a Direct Repressor of SHH Effectors Gli1
and Gli2
To gain insight into the underlying mechanisms, we examined
gene expression among FACS-purified GNP populations in con-
trol and Bcl6 KOmice at P7, usingMath1-GFP knockin mice that
express GFP exclusively in Math1+ GNP (Figures 2A, 2B, and
S2A; Rose et al., 2009).We focused our analysis on genes known
to be involved in GNP proliferation and differentiation (Ben-Arie
et al., 1997; Flora et al., 2009) as well as on known BCL6-target
genes in other contexts, in particular TP53 and ATR that are
implicated in the physiological and oncogenic effects of BCL6
in B cell lineages (Phan and Dalla-Favera, 2004; Ranuncolo
et al., 2007; Sakano et al., 2010; Tiberi et al., 2012). This revealed
little difference in the levels of expression of most genes exam-
ined (including genes related to the BMP, WNT, and NOTCH
pathways, as well as Trp53 and Atr) in Bcl6 KO compared to
WT GNP, except a strong upregulation of Gli1 and Gli2, the
main effectors of the SHH pathway (Figures 2C and S2B). In
addition, Ccnd2, which is a downstream target of BCL6 in B
cells, was found to be upregulated in the Bcl6 KO cells (Nahar
et al., 2011), whileCdkn1b, which encodes the cyclin-dependent
kinase inhibitor p27, was found to be downregulated in the Bcl6
KO cells, reflecting defective cell cycle exit. Overall, these data
indicate that the SHH pathway appears to be a major target of
Figure 1. BCL6 Is Required for Proper Cerebellum Development
(A) Immunohistochemistry staining of sagittal sections of Bcl6 WT cerebellum at P7 with BCL6 antibody. Scale bar, 1 mm.
(B) Confocal immunofluorescence staining for BCL6 with either Ki67 or NeuN of sagittal sections of P7 WT cerebellum. Scale bars, 250 mm.
(C and D) Confocal immunofluorescence staining for BCL6 and/or NeuN of sagittal sections of P7WT (C) andBcl6 KO (D) cerebellum. Scale bars, 100 mm. Arrows
point to NeuN+ neurons in EGL.
(E) Quantification of the number of NeuN+ cells in EGL Bcl6 WT and KO brains at P7; n = 4.
(F) Quantification of the IGL area (NeuN+ cells) of the cerebellum in Bcl6 WT and KO brains at P7; n = 4, brains.
(G) Immunofluorescence analysis of sagittal sections ofBcl6WTandKObrains at P7 for EdUandKi67. EdUwas injected 24 hr before perfusion. Scale bars, 50 mm.
(H) Quantification of cell cycle exit index (EdU+Ki67/EdU+) in Bcl6WT and KO brains 24 hr after injection of EdU in four different regions of the cerebellum; n = 3.
Data are means ± SEM. Arrows point to EdU+ Ki67 cells.
*p < 0.05, **p < 0.01. See also Figure S1.
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BCL6 Suppresses Sonic Hedgehog MedulloblastomaBCL6 in the GNP lineage. Confirming this, BCL6 overexpression
in GNP resulted in a strong repression of Gli1 and Gli2, while
most other tested genes remained unchanged (Figures 2D–2F).CaWe next examined whether Gli1 and Gli2 repression was
causally linked to the proneurogenic effects of BCL6. The
double knockdown of Gli1 and Gli2 resulted in increasedncer Cell 26, 797–812, December 8, 2014 ª2014 Elsevier Inc. 799
Figure 2. BCL6 Induces Neurogenesis through Gli1 Repression
(A) Immunofluorescence staining for GFP and Hoechst of sagittal section of cerebellum from a Math1-GFP+ mouse at P7. Scale bar, 1 mm.
(B) Representative FACS histograms showing GFP expression in cerebellar cells isolated fromWT, Bcl6WT;Math1-GFP+, and Bcl6 KO;Math1-GFP+ mice at P7.
Postsort analysis was performed by reanalyzing the GFP profile of 10,000 sorted cells.
(C) Quantitative real-time PCR analysis forMath1, Gli1,Gli2,Mycn, Ptch1, Bcl6, Trp53, Atr, Neurod1, Hes5, and Hes1 from FACS-sortedMath1-GFP+ cells from
Bcl6 WT and KO cerebellum at P7; n = 3.
(D and E) Immunofluorescence analysis for GFP and NeuN, 72 hr after nucleofection with pCIG (D) or pCIG-BCL6 (E) of ex vivo culture of cerebellar cells fromWT
P7 mice. Scale bars, 50 mm.
(F) Quantitative real-time PCR analysis forMath1, Gli1, Gli2,Mycn, Neurod1, Trp53, Atr, Hes5, and Hes1 from FACS-sorted GFP+ cells 72 hr after nucleofection
with pCIG or pCIG-BCL6 of ex vivo culture of cerebellar cells from WT P7 mice; n = 3.
(G and H) Immunofluorescence analysis for Hoechst, GFP, and NeuN, 72 hr after nucleofection with pCIG-Gli1 (G) or pCIG-BCL6 + pCIG-Gli1 (H) of ex vivo culture
of cerebellar cells from WT P7 mice. Scale bars, 50 mm.
(I) Histograms show the percentage of cells expressingNeuN among all GFP+ cells 72 hr after nucleofection with pCIG, pCIG-BCL6, pCIG-Gli1, and pCIG-BCL6 +
pCIG-Gli1 of ex vivo culture of cerebellar cells from WT P7 mice; n = 4.
Data are means ± SEM. *p < 0.05, **p < 0.01. See also Figure S2.
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Figure 3. BCL6 Directly RepressesGli1/Gli2
Expression
(A) Schematic representation of the genomic re-
gion of mouse Gli1 and Gli2, showing the exons in
red and the potential BCL6 binding sites in yellow.
Primers used in ChIP assay are presented by thick
arrows.
(B–F) ChIP analysis of the putative BCL6-binding
sites in the Math1, Gli1, Gli2, Hes5, and Trp53
promoters in Bcl6 WT and KO cerebellar tissue at
P7 with anti-BCL6 (B), SIRT1 (C), H1.4K26ac (D),
H4K16ac (E), and BCOR (F) antibodies; n = 3.
(G) Quantitative real-time PCR analysis for Gli1,
Gli2,Math1, andNeurod1 from FACS-sortedGFP+
cells 72 hr after nucleofection with pCIG + pSCV2-
shCtr, pCIG-BCL6+pSCV2-shCtr, pCIG+pSCV2-
shBCoR, and pCIG-BCL6 + pSCV2-shBCoR of
ex vivo culture of cerebellar cells fromWTP7mice;
n = 3.
(H) Histograms show the percentage of GFP+ cells
expressing NeuN 72 hr after the nucleofection with
pCIG + pSCV2-shCtr, pCIG-BCL6 + pSCV2-shCtr,
pCIG+pSCV2-shBCoR,andpCIG-BCL6+pSCV2-
shBCoR of ex vivo culture of cerebellar cells from
WT P7 mice; n = 3.
Data are means ± SEM. *p < 0.05, **p < 0.01. See
also Figure S3.
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BCL6 Suppresses Sonic Hedgehog MedulloblastomaGNP neurogenesis, thus mimicking BCL6 gain of function
(Figure S2C–S2E), while overexpression of Gli1 together with
BCL6 completely blocked BCL6-dependent neurogenesis
(Figures 2D–2I). These data indicate that BCL6 exerts its ef-
fects in GNP by repressing SHH effectors, raising the question
of the underlying molecular mechanism. In silico inspection of
Gli1 and Gli2 regulatory regions revealed the presence of
several BCL6 binding sites located close to the transcriptional
starting points (Figure 3A). Using BCL6-chromatin immunopre-
cipitation (ChIP) experiments from WT and Bcl6 KO P7 cere-Cancer Cell 26, 797–812,bellum, we found a specific enrichment
directly in two sites in the Gli1 promoter
and in one site in the Gli2 first intron,
while no enrichment could be detected
in putative binding sites located in
Hes5, Math1, or Trp53 promoters (Fig-
ure 3B). These data indicate that BCL6
repression on Gli1 and Gli2 likely re-
flects a direct action on their regulatory
regions.
BCL6 Neurogenic Activity Requires
SIRT1 Deacetylase and BCOR
Corepressor
We previously found that BCL6 can
repress transcription by recruiting the
SIRT1 deacetylase (Tiberi et al., 2012).
Using coimmunoprecipitation (coIP) on
P7 mouse cerebellar extracts, we de-
tected BCL6 in the same complex as
SIRT1 (Figure S3A). ChIP experiments
on chromatin prepared from cerebellartissue at P7 revealed that SIRT1 was enriched at the BCL6
binding site of the Gli1 and Gli2 promoters, and that this
enrichment was markedly reduced in Bcl6 KO cerebellum (Fig-
ure 3C), whereas the total levels of SIRT1 appeared to be un-
changed (Figure S3A). We next determined whether BCL6/
SIRT1 could influence chromatin acetylation patterns at the
Gli1 and Gli2 regulatory regions. ChIP analysis revealed strong
enrichment of acetylated H1.4K26Ac and H4K16Ac on Gli1
and Gli2 promoters in Bcl6 KO P7 cerebellum compared
with WT (Figures 3D and 3E). Thus, the chromatin aroundDecember 8, 2014 ª2014 Elsevier Inc. 801
Figure 4. BCL6 Represses DAOY Cells Proliferation through Gli1 Repression
(A) Immunofluorescence staining for GFP and pH3 of DAOY cells 5 days after nucleofection with pCIG, pCIG-Gli1, pCIG-BCL6, and pCIG-BCL6 + pCIG-Gli1.
Scale bars, 60 mm.
(B) Higher magnification of immunofluorescence staining for GFP and/or pH 3, Hoechst of panel (A). Scale bars, 20 mm.
(C) Histograms show the number of GFP+ cells 5 days after the nucleofection of DAOY cells with pCIG, pCIG-BCL6, pCIG-Gli1, and pCIG-BCL6 +pCIG-Gli1; n = 4.
(legend continued on next page)
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BCL6 Suppresses Sonic Hedgehog Medulloblastomathe Gli1 and Gli2 promoters was remodeled in a BCL6-depen-
dent manner.
BCL6 also previously was shown to repress transcription
through direct interactions with NCOR corepressor complex
proteins, in particular BCOR (Huynh and Bardwell, 1998; Huynh
et al., 2000). To test BCOR’s contribution, we first performed
coIP and found that BCOR bound BCL6 in the cerebellum (Fig-
ure S3B). Using ChIP, we observed recruitment of BCOR to
the Gli1 and Gli2 promoters in the cerebellum, which was
strongly decreased in Bcl6 KO mice compared to control (Fig-
ure 3F). Furthermore, coIP demonstrated the presence of
BCOR in the same complex as SIRT1 and this interaction was
strongly reduced in Bcl6 KO mice (Figure S3C). To test the rele-
vance of these findings to neurogenesis, we next knocked down
BCOR in GNP during BCL6-induced neurogenesis, which
completely abolished the ability of BCL6 to repress Gli1 and
Gli2 (Figures 3G and S3D) and to induce neurogenesis in
cultured GNP (Figures 3H and S3E). We then treated GNP with
the SIRT1 inhibitor EX-527 (Min et al., 2010), which also resulted
in the complete block of neurogenesis induced by BCL6 (Fig-
ure S3F). These data indicate that BCL6 converts GNP into neu-
rons through the recruitment of BCOR and SIRT1 at the Gli1 and
Gli2 promoters. We also tested the effect of BCOR overexpres-
sion or SIRT1 activation alone on ex vivo cultures of GNP (Fig-
ures S3G and S3H). No effect could be detected on neurogene-
sis, suggesting that the upregulation of BCL6, but not of BCOR
or SIRT1, is a key event during GNP neurogenesis.
BCL6/BCOR/SIRT1 Complex Suppresses Growth of
Human MB Cells through Gli1 and Gli2 Repression
As aberrant activation of SHH signaling inGNP is thought to be at
the origin of SHHMB (Schu¨ller et al., 2008; Yang et al., 2008), we
next examined the potential implication of BCL6 in their growth
and development. We first tested the effects of BCL6 on the hu-
man MB DAOY cell line (Wang et al., 2012), which is sensitive to
SHH pathway inhibition (Figures S4A and S4B). Overexpression
of BCL6 in DAOY cells resulted in strong suppression of their
growth and mitotic activity (Figures 4A–4D), as well as increased
expression of neural differentiation markers, while TP53/ATR re-
mained unaffected (Figure 4E). Cell apoptosis did not appear to
be affected (Figure S4C; percentage cleaved caspase 3+ cells:
Ctr, 2.23 ± 0.25; BCL6, 1.89 ± 0.18; n = 8). Importantly, the tumor
cell growth inhibitory effect was associated with GLI1 and GLI2
repression (Figure 4E), and was completely abrogated by coex-
pression of Gli1 (Figures 4A–4E), thereby linking repression of
GLI genes to the growth suppressive effects of BCL6.
In line with this, we tested whether the antigrowth effect of
BCL6 was specific to SHH-sensitive MB cell lines. We examined
the effects of BCL6 on the humanMB cell line D341-MED, which(D) Histograms show the percentage of GFP+ cells expressing pH 3, 5 days after
BCL6 + pCIG-Gli1; n = 4.
(E) Histograms show quantitative real-time PCR analysis for GLI1, GLI2, NEUROD
pCIG-BCL6; n = 4.
(F) Schematic representation of the genomic region of humanGLI1 andGLI2, sho
assay are presented by thick arrows.
(G–K) ChIP analysis of the putative BCL6-binding sites in theMATH1,GLI1,GLI2,H
pCIG-BCL6 with anti-BCL6 (G), BCOR (H), SIRT1 (I), H1.4K26ac (I), and H4K16a
Data are means ± SEM. *p < 0.05, **p < 0.01. See also Figure S4.
Cawas proposed to be derived from a group 3 MB (Snuderl et al.,
2013), and could not detect any effect of BCL6 or cyclopamine,
in conditions similar to those used for DAOY cells, on these cells
(Figures S4D–S4F). In silico inspection of the human GLI1 and
GLI2 regulatory regions revealed the presence of two bona fide
BCL6 binding sites in GLI1 promoter region (like in the mouse)
and only one in the GLI2 promoter region (instead of three as
in the mouse)(Figure 4F). We next performed ChIP analyses for
BCL6, BCOR, and SIRT1 in DAOY cells following expression of
BCL6 (Figures 4G–4I). This revealed that overexpressed BCL6
was strongly enriched at both GLI1 and GLI2 promoters, like in
the mouse, while no enrichment could be found in other target
gene promoters, such asHES5 and TP53 (Figure 4G). Moreover,
BCL6 overexpression triggered the recruitment of BCOR and
SIRT1 toGLI1 andGLI2 promoter regions, whichwas associated
with decreased histone acetylation patterns (Figures 4H–4K).
Importantly, the effects of BCL6 on repressing GLI1 expression
and MB cell growth were completely blocked following either
BCOR knockdown (Figures 5A–5D and S5A) or SIRT1 knock-
down and inhibition (Figures S5B–S5H). Also, BCOR knockdown
effects were fully rescued by overexpressing the WT BCOR but
not a BCORmutant devoid of its putative BCL6 binding site (Fig-
ures 5A–5E) that was recently identified in SHHMB (Jones et al.,
2012). Altogether these data indicate that BCL6, acting together
with SIRT1/BCOR complexes, can repress GLI1 and GLI2
expression and thereby suppress the growth of a human SHH
MB cell line.
BCL6 Overexpression Inhibits the Development of SHH
MB In Vivo
To validate these findings in vivo, we turned to a well-established
mouse model of SHH MB (Schu¨ller et al., 2008), where a consti-
tutively active mutant form of SHH effector Smo (SmoM2) can be
selectively expressed in the GNP lineage, by crossing Rosa26S-
moM2 mice (Jeong et al., 2004) with Math1-creER mice (Mac-
hold and Fishell, 2005). Using this model, SmoM2 induction at
P4 resulted in GNP overgrowth and MB-like, highly proliferating
tumors in all cases examined (Figures 6A–6C). We then tested
the effect of BCL6 overexpression using a mouse model that al-
lowed doxycyclin- (Dox-)inducible ubiquitous expression of hu-
man BCL6 by crossing tet-o-BCL6 mice (Baron et al., 2004)
with Rosa26 rtTA (Hochedlinger et al., 2005; Figure 6D). Strik-
ingly, the mice that overexpressed SmoM2 together with BCL6
showed a strong reduction in tumor formation at P14 (Figure 6E),
together with a decreased proliferation (Figure 6F) and an
increased expression of neuronal differentiation markers (Fig-
ures 6B, 6C, and 6E). Furthermore, Kaplan-Meier analysis re-
vealed a doubling of the survival time following overexpression
of BCL6, despite ongoing SmoM2 expression (p < 0.001;the nucleofection of DAOY cells with pCIG, pCIG-BCL6, pCIG-Gli1, and pCIG-
1, ZIC1, TP53, and ATR 5 days after nucleofection of DAOY cells with pCIG or
wing the exon in red and the BCL6 binding sites in yellow. Primers used in ChIP
ES5, and TP53 promoters and introns in DAOY cells nucleofected with pCIG or
c (K) antibodies; n = 3.
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Figure 5. BCL6 Requires BCOR to Repress Proliferation of DAOY Cells
(A) Immunofluorescence staining for GFP and pH 3 of DAOY cells 5 days after nucleofection with pCIG + pSCV2-shCtr, pCIG-BCL6 + pSCV2-shCtr, pCIG +
pSCV2-shBCOR, pCIG-BCL6 + pSCV2-shBCOR, pCIG-BCL6 + pSCV2-shBCOR + pCIG-BCOR-FL (full-length), and pCIG-BCL6 + pSCV2-shBCOR + pCIG-
BCOR-TN (truncated). Scale bars, 60 mm. Arrows point to GFP+ pH 3+ cells.
(B–D) Histograms show the number of GFP+ cells (B), the percentage of GFP+ cells expressing pH 3 (C), or quantitative real-time PCR analysis forGLI1 andGLI2
(D) 5 days after nucleofection of DAOY cells with pCIG + pSCV2-shCtr, pCIG-BCL6 + pSCV2-shCtr, pCIG + pSCV2-shBCOR, pCIG-BCL6 + pSCV2-shBCOR,
pCIG-BCL6 + pSCV2-shBCOR + pCIG-BCOR-FL (full-length), and pCIG-BCL6 + pSCV2-shBCOR + pCIG-BCOR-TN (truncated); n = 4.
(E) Graph shows quantification of GFP+ cells after nucleofection of DAOY cells with pCIG + pSCV2-shCtr, pCIG-BCL6 + pSCV2-shCtr, pCIG + pSCV2-shBCOR,
pCIG-BCL6 + pSCV2-shBCOR, pCIG-BCL6 + pSCV2-shBCOR + pCIG-BCOR-FL (full-length), and pCIG-BCL6 + pSCV2-shBCOR + pCIG-BCOR-TN
(truncated); n = 4.
Data are means ± SEM. *p < 0.05, **p < 0.01. See also Figure S5.
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BCL6 Suppresses Sonic Hedgehog MedulloblastomaFigure 6G). Interestingly, BCL6 overexpression also resulted in
suppression of proliferation in the EGL in mice without SmoM2
activation, suggesting that BCL6 acts similarly on normal and
oncogenic proliferative patterns of GNP (Figure 6F). We then
characterized in more detail the pattern of expression of BCL6
and Gli1 in this context (Figure S6A). BCL6 was found to be ex-
pressed 2 days following Dox injection (Figures S6B–S6E),
including in the internal compartment of the tumor, while Gli1
was repressed following BCL6 induction (Figures S6F–S6I). In
contrast, at P14 (thus 7 days following Dox induction), ectopic
expression of BCL6 in the internal compartment of the tumor
was no longer detectable (Figures S6J–S6M), while Gli1 was ex-
pressed in the tumor (Figures S6N–S6Q).
We next testedwhether BCL6 also is able to reduce the growth
of a tumor that is already established. For this purpose, we
induced transient ectopic BCL6 expression 10 days after the
SmoM2 activation (Figure 7A). This resulted in strong reduction
in tumor growth (Figures 7B–7E), decreased proliferative pat-
terns (although not to control levels) (Figure 7F), and increased
survival time (p < 0.001; Figure 7G). This also increased expres-
sion of neuronal differentiation markers together with repression
of Gli1 and Gli2, while Trp53 and Atr remained unchanged (Fig-
ures 7B–7E and 7H). We then characterized in more detail the
pattern of expression of BCL6 and Gli1 in this context (Fig-
ure S7A). BCL6 was found to be expressed 2 days following
Dox injection (Figures S7B–S7E), including in the internal
compartment of the tumor, while Gli1 was repressed following
BCL6 induction (Figures S7F–S7H). In contrast, by P21 (Figures
S7I–S7N) and P40 (Figures S7O–S7T), 7 and 26 days following
Dox induction, respectively, ectopic expression of BCL6 in the
internal compartment of the tumor was no longer detectable
(Figures S7B, S7I–S7K, and S7O–S7Q), while Gli1 was largely
expressed throughout the tumor (Figures S7L–S7N and S7R–
S7T). Finally, given the transient nature of BCL6 overexpression,
we tried to test the effect of more sustained overexpression of
BCL6 by performing experiments where Dox was injected
several times (at P14, P16, P18, and P20), following tumor induc-
tion at P4. However, no ectopic expression of BCL6 could be de-
tected beyond 2 days following induction, and, conversely, no
additional increase in the survival of the mice could be obtained,
when compared with the data obtained with a single injection at
P14 (data not shown).
Overall, these data indicate that BCL6 transient overexpres-
sion can strongly delay and inhibit MB formation and develop-
ment in vivo. BCL6 appears to act not only by reducing the
pool of GNP but also by reducing the growth of established tu-
mors, in part by promoting differentiation and possibly through
other mechanisms, such as reduced proliferation. However
these effects are only transient, most likely because of the tran-
sient expression of the BCL6 transgene, which could explain tu-Figure 6. BCL6 Represses SHH MB Development
(A) Schematic representation of the experimental protocol. Mice were injected w
(B–E) Immunofluorescence staining for Hoechst, Ki67, and pH 3 or Hoechst, Ki67
SmoM2;tet-o-BCL6+ (E) mice after injection of tamoxifen and doxycyclin at P4.
(F) Quantification of pH 3+ cells within the EGL at P14 in WT, SmoM2, SmoM2;tet-
n = 4.
(G) Survival curve of WT (n = 17), tet-o-BCL6+ (n = 5), SmoM2 (n = 12), and SmoM2
mice are Math1-creER+;rtTA+. Scale bars, 200 mm. Data are means ± SEM. *p <
806 Cancer Cell 26, 797–812, December 8, 2014 ª2014 Elsevier Inc.mor growth after longer periods following the Dox treatment. It
will be interesting to design for future studies a model where
BCL6 is expressed in a constitutive fashion in the tumor, to
test whether and how the tumors would then escape its onco-
suppressive effects.
BCL6 Is Required in GNP to Suppress SHH MB In Vivo
To test the importance of endogenous BCL6 during MB forma-
tion, we used a mouse model where BCL6 was inactivated spe-
cifically in the GNP lineage by crossing Bcl6 conditional KO
(Bcl6lox/lox) (Kaji et al., 2012) with Math1-creER mice (Machold
and Fishell, 2005) and with tamoxifen injection at E15.5. Bcl6
conditional KO mice examined at P21 displayed a smaller cere-
bellum compared toWT, like the germlineBcl6KO (Figures S8A–
S8C), but did not display any sign of tumor formation up to
12 weeks of age. We then combined Bcl6 inactivation with
disruption of Trp53 to reveal tumor formation in the cerebellum
(Wetmore et al., 2001). Although Trp53 disruption alone does
not lead to MB in the mouse (Marino et al., 2000; Romer et al.,
2004; Wetmore et al., 2001), the combined disruption of Bcl6
and Trp53 resulted in cerebellar tumor formation in more than
half (n = 5/9) of the mice examined at 12 weeks of age (Figures
8A–8I). The location of the tumors was consistently found at
the periphery of the cerebellum, and overproliferation patterns
together with strong expression of Gli1 and Mycn further sug-
gested that they correspond to SHH MB (Figures 8G–8I and
S8D–S8F). Importantly, no tumor was detected in any WT (n =
7), Bcl6 KO (n = 8), or Trp53 KO (n = 11) mice (Figures S8G
and S8H and Table S1). Tumor mass was much increased by
20 weeks in Trp53;Bcl6 double KO mice (n = 2/2) (Figures 8J–
8O), while no tumor was detected in any WT (n = 1), Bcl6 KO
(n = 2), or Trp53 KO (n = 2) mice. These data indicate that endog-
enous BCL6 is required to prevent MB formation in vivo, strongly
suggesting that it acts as a genuine oncosuppressor (Gilbertson
and Ellison, 2008).
DISCUSSION
Our data show that the BCL6 protein acts as an intrinsic neuronal
differentiating factor and tumor suppressor through direct
repression of SHH signaling in the GNP lineage. In each case,
BCL6 was found to act through the same molecular mechanism,
i.e., through the recruitment of BCOR corepressor and SIRT1
histone deacetylase, thereby leading to epigenetic repression
of Gli1 and Gli2 SHH effectors. These parallels strikingly illustrate
how the same pathway can act as a differentiating factor and as
a tumor suppressor, as previously shown for other genes and tu-
mors (Asselin-Labat et al., 2007; Batlle et al., 2005; Bossuyt
et al., 2009; Emmenegger et al., 2013; Kouros-Mehr et al.,
2008; Zhao et al., 2008). BCL6 mechanisms of action alsoith tamoxifen and doxycyclin at P4 and analyzed at P14.
, and NeuN of sagittal sections of P14 WT (B), SmoM2 (C), tet-o-BCL6+ (D), or
o-BCL6+, and tet-o-BCL6+ mice injected with tamoxifen and doxycyclin at P4;
;tet-o-BCL6+ (n = 14) mice injected with tamoxifen and doxycyclin at P4. All the
0.05, **p < 0.01. See also Figure S6.
(legend on next page)
Cancer Cell
BCL6 Suppresses Sonic Hedgehog Medulloblastoma
Cancer Cell 26, 797–812, December 8, 2014 ª2014 Elsevier Inc. 807
Cancer Cell
BCL6 Suppresses Sonic Hedgehog Medulloblastomanotably mirror those of MATH1/Atoh1, which is required for the
specification and expansion of GNP aswell as forMB tumorigen-
esis through the positive regulation of Gli factors (Flora et al.,
2009).
In the context of normal brain development, our data point to
BCL6 as an important component of proper neurogenesis, both
in the cerebral and cerebellar cortex. Surprisingly, however, its
molecular mechanism of action is completely distinct in the
two brain regions: while in the cerebral cortex BCL6 acts mainly
through inhibition of Hes genes downstream of the Notch
pathway, in GNP it targets SHH effectors Gli1 and Gli2. This is
consistent with the fact that the Notch pathway appears to
have little impact on GNP neurogenesis, despite expression of
Hes genes in these cells (Julian et al., 2010). Interestingly, the ef-
fect of BCL6 is conceptually the same in each case, i.e., it ap-
pears to act by decreasing the competence of neural progenitors
to respond to proliferative/self-renewal signals (NOTCH or SHH),
thereby promoting their neurogenic conversion.
In the context of oncogenic development, BCL6 stands out as
it is both necessary for and capable of preventing MB develop-
ment in vivo. Our finding that BCL6 requires BCOR for SHH
signaling suppression in GNP is particularly relevant in the light
of recent findings that BCOR is mutated in up to 7% of SHH
MB cases (Kool et al., 2014; Northcott et al., 2012a; Olson,
2014; Pugh et al., 2012). Our data strongly suggest that BCOR
mutations facilitate MB development through decreased repres-
sion of Gli1 and Gli2. Intriguingly, additional mutations were
found in genes encoding other components of the N-COR com-
plex, such as SMRT and LDB1 (Northcott et al., 2012a), suggest-
ing that they could act in the same BCL6-dependent repressive
complex. On the other hand, no mutations of BCL6 were
described in these studies centered on exonic regions, but
BCL6 expression previously was shown to be downregulated
in SHHMB (Kho et al., 2004; Schu¨ller et al., 2006). It will be inter-
esting to explore which mechanisms, whether genetic or epige-
netic, are responsible for BCL6 downregulation in MB, and to
test whether the levels of expression and functionality of the
BCL6/BCOR/SIRT1 complex may be relevant for the tailoring
of treatments of SHH MB (Olson, 2014).
Our data and previous findings from others (Basso and Dalla-
Favera, 2012) illustrate how the same factor can act as either an
oncogene or a tumor suppressor, as previously shown for other
proteins such as NOTCH1 (Radtke and Raj, 2003), MATH1 (Bos-
suyt et al., 2009; Flora et al., 2009), ZBTB7/Pokemon (Maeda
et al., 2005; Wang et al., 2013), and HDAC1 (Santoro et al.,
2013). Indeed BCL6 is a well-established oncogene in some
forms of B cell lymphoma (Phan and Dalla-Favera, 2004; Basso
and Dalla-Favera, 2012). In this context, BCL6 is thought to actFigure 7. BCL6 Represses SHH MB Progression
(A) Schematic representation of the experimental protocol. Mice were injected w
(B–E) Immunofluorescence staining for either Hoechst, Ki67, and pH3 or Hoechst,
or SmoM2;tet-o-BCL6+ (E) mice after injection of tamoxifen at P4 and doxycyclin
(F) Quantification of pH 3+ cells within the EGL at P21 inWT, SmoM2,SmoM2;tet-o
P14; n = 4.
(G) Survival curve ofWT (n = 15), tet-o-BCL6+ (n = 7), SmoM2 (n = 18), and SmoM2
(H) Quantitative real-time PCR analysis forMath1, Gli1, Gli2, Mycn, Ptch1, Neuro
mice injected with tamoxifen at P4 and doxycyclin at P14; n = 3. All the mice are
Scale bars, 200 mm. Data are means ± SEM. *p < 0.05, **p < 0.01. See also Figu
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in DNA damage sensing and apoptosis, in particular TP53 and
ATR, thus favoring persistent tolerance to DNA damage and,
thereby, the accumulation of additional oncogenic mutations
(Phan and Dalla-Favera, 2004; Basso and Dalla-Favera, 2012;
Cerchietti et al., 2008; Hatzi and Melnick, 2014; Ranuncolo
et al., 2007). Similarly BCL6 is involved in several forms of leuke-
mia where BCL6-mediated repression of p53 was shown to pro-
mote leukemia stem cell survival (Duy et al., 2011; Hurtz et al.,
2011). Interestingly, our data indicate that, in the case of cere-
bellar development and MB, p53 and ATR appeared to be unaf-
fected by BCL6. The double-edged effects of BCL6 seem to be
best explained by the fact that BCL6 represses a distinct set of
transcriptional targets depending on the cellular context. It will
be most interesting to dissect the underlying molecular mecha-
nisms, which likely involve cell-specific chromatin modifiers or
cofactors (Swaminathan et al., 2013), as these could be used
in principle to suppress the ability of BCL6 to act in an oncogenic
fashion in specific contexts.
The BCL6 dual effects could have additional clinical implica-
tions, since BCL6 inhibition using specific inhibitors was pro-
posed as a therapeutic strategy for lymphoma (Robinson et al.,
2012), but also some forms of leukemia (Duy et al., 2011). While
it is unlikely that BCL6 inhibition would lead to MB in adult pa-
tients, since GNP are no longer present, future work should
investigate whether BCL6 function is only required in GNP, and
not postmitotic granule neurons, to prevent MB formation. Be-
sides and notably, BCL6 inhibition also was proposed to be
used against some forms of acute lymphoblastic leukemia
(Duy et al., 2011), which include pediatric forms as well. On the
other hand, while SHH MB could in principle be treated with
SHH receptor antagonists (Ng and Curran, 2011; Rudin et al.,
2009), they tend to acquire resistance to the treatment, mainly
through mutations in SMO. The BCL6/BCOR/SIRT1 complex,
by its capacity to block SHH signaling at the key level of Gli1
and Gli2 expression, may thus constitute an attractive target to
activate in SHH-dependent tumors, which tend to acquire resis-
tance to SHH receptor antagonists (Ng and Curran, 2011; Rudin
et al., 2009).
EXPERIMENTAL PROCEDURES
Cell Culture
DAOY cell were purchased from ATCC (HTB-186) and were routinely propa-
gated in Eagle’s minimal essential medium (Invitrogen) supplemented with
10% (v/v) fetal bovine serum (Invitrogen) and 1% (v/v) penicillin/streptomycin
(15070-063; Invitrogen). DAOY cells (1 3 106) were nucleofected with 10 mg
of DNA using a Nucleofector 2b Device (Lonza) and Cell Line Nucleofector
Kit VCA-1005 (Lonza), and plated onto coverslips in a 12-well plate (4 3 104ith tamoxifen at P4, doxycyclin at P14, and analyzed at P21.
Ki67, and NeuN of sagittal sections of P21WT (B),SmoM2 (C), tet-o-BCL6+ (D),
at P14.
-BCL6+, and tet-o-BCL6+mice injected with tamoxifen at P4 and doxycyclin at
;tet-o-BCL6+ (n = 13) mice injected with tamoxifen at P4 and doxycyclin at P14.
d1, Zic1, Trp53, and Atr from cerebellum of SmoM2 and SmoM2;tet-o-BCL6+
Math1-creER+;rtTA+.
re S7.
(legend on next page)
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BCL6 Suppresses Sonic Hedgehog Medulloblastomacells for each well). Cerebella from P7 mice were removed aseptically and
incubated at 37C with trypsin (Invitrogen) for 10 min. The trypsin was neutral-
ized with PBS serum 10% and tissue was triturated using pipettes of
decreasing bore size to obtain a single-cell suspension. The cells were centri-
fuged at room temperature and 1 3 106 cells were nucleofected with 10 mg of
DNA using Nucleofector 2b Device (Lonza) and Mouse Neural Stem Cells Kit
VPG-1004 (Lonza), and plated onto poly-L-lysine/laminin-coated coverslips
in a 12-well plate (2 3 105 cells for each well). After nucleofection, the cells
were maintained in neurobasal media (Invitrogen) supplemented with 1%
(v/v) penicillin/streptomycin (Invitrogen), B27 (Invitrogen), and SHH-N (R&D
Systems, 3 mg/ml). The cells were treated for 72 hr with 10 mM resveratrol
(R5010, Sigma-Aldrich [Lagouge et al., 2006]). Additional details are available
in the Supplemental Experimental Procedures.
Plasmids
The coding sequence of mouse BCL6 was amplified by PCR from cDNA,
sequence verified, and cloned into pCAG-IRES-GFP (pCIG). The coding
sequence of mouse Gli1 was amplified by PCR from cDNA and cloned into
pCIG. The coding sequence of human BCOR was amplified by PCR from a
plasmid of Dr. V.J. Bardwell (University of Minnesota) and cloned into
pCIG. Truncated BCOR was amplified by PCR from WT BCOR. Double-
stranded oligonucleotides coding for mouse BCoR 30-UTR shRNA, human
BCOR 30-UTR shRNA, control shRNA, mouse Gli1 shRNA, and mouse Gli2
shRNA were cloned downstream of the U6 promoter into the pSilencer2.1-
CAG-Venus (pSCV2) plasmid according to the pSilencer instructions from
Ambion. Additional details are available in the Supplemental Experimental
Procedures.
Immunofluorescence Staining and Immunohistochemistry
Ex vivo cerebellar cells and DAOY cells were fixed in 4% paraformaldehyde
in PBS (w/v) for 30 min and washed three times in PBS. P7, P14, P16, P21,
P40, 12- and 20-week-old mice were anesthetized with an overdose of ke-
tamine/xylazine and were fixed by perfusion with 4% paraformaldehyde in
PBS; when appropriate, the cerebella were either cryoprotected in 30%
(w/v) sucrose in water (Merck) or embedded in paraffin (brains were dehy-
drated with ethanol, then kept sequentially in ethanol/toluene, toluene/
paraffin, and paraffin solutions). Immunofluorescence stainings were per-
formed on slides with 20-mm-thick cryosections. Blocking solution consisted
of PBS supplemented with 5% (v/v) horse serum (Invitrogen), 0.3% (v/v)
Triton X-100 (Sigma), and 3% (w/v) BSA (Sigma). Antibody solution con-
sisted of PBS supplemented with 1% horse serum, 0.1% (v/v) Triton
X-100, and 3% BSA. Primary antibodies were incubated overnight at 4C
and secondary for 2 hr at 15C–25C. Nuclei were stained with bisbenzimide
(Hoechst 33258; Sigma). Sections and coverslips were mounted with glycer-
gel (Dako). Additional details are available in the Supplemental Experimental
Procedures.
Western Blot, CoIP, ChIP, ChIP Quantitative PCR
Cerebella from P7 mice were removed aseptically and the cells were brought
to a single cell suspension by pipetting in PBS. Western blot and coIP were
performed on dissected P7 cerebellum. ChIP was performed as described
previously (Tiberi et al., 2012) on dissected P7 cerebellum or DAOY cells. Addi-
tional details are available in the Supplemental Experimental Procedures.Figure 8. BCL6 Is Required to Suppress MB Development
(A–C) Hematoxylin and eosin staining of sagittal sections of cerebellum from 12-w
WT (B), and Math1-creER+;Bcl6lox/lox;Trp53lox/lox (C) mice. Scale bars, 500 mm. A
(D–F) Immunofluorescence staining for NeuN and Ki67 of sagittal sections of
creER+;Bcl6lox/lox;Trp53 WT (E), and Math1-creER+;Bcl6lox/lox;Trp53lox/lox (F) mice
(G–I) Immunohistochemistry staining of sagittal sections of cerebellum from 12-w
WT (H), and Math1-creER+;Bcl6lox/lox;Trp53lox/lox (I) mice with Gli1 antibody. Sca
(J–L) Hematoxylin and eosin staining of sagittal sections of cerebellum from 20-w
WT (K), and Math1-creER+;Bcl6lox/lox;Trp53lox/lox (L) mice. Scale bars, 500 mm. A
(M–O) Immunofluorescence staining for Hoechst, pH 3, and Ki67 of sagittal sec
Math1-creER+;Bcl6lox/lox;Trp53WT (N), andMath1-creER+;Bcl6lox/lox;Trp53lox/lox
when the embryos were at E15.5.
Scale bars, 500 mm. Arrows point to abnormal tissue. See also Figure S8 and Ta
810 Cancer Cell 26, 797–812, December 8, 2014 ª2014 Elsevier Inc.RNA Isolation and Quantitative Real-Time PCR
For total RNA preparation, DAOY cells and cerebellum frommice were lysed in
RNeasy lysis buffer + 1% (v/v) b-mercaptoethanol, andRNAwas isolated using
RNeasy RNA preparationminikit (QIAGEN) according to themanufacturer’s in-
structions. Reverse transcriptionwas done using Superscript II kit and protocol
(Invitrogen). Quantitative PCR (qPCR) was performed in duplicate using Power
SybrGreen Mix and a 7500 Real-Time PCR System (Applied Biosystems).
Results are presented as linearized Ct values normalized to the housekeeping
mouse Tbp and human YWHAZ and the indicated reference value (2DDCt).
Flow Cytometry and Cell Sorting
Analytical FACS studies were carried out using an LSR Fortessa supported by
the FACSDiva software (BD Biosciences). The PE-coupled cleaved caspase 3
staining was performed according to the manufacturer’s recommendations
(BDPharmingen). Apoptosis positive control was obtained following cells treat-
ment with either Okadaic acid 50 nM or Cisplatin 50 mM for 8 hr before analysis.
Cell sorting was performed using a FACS Aria I cell sorter supported by the
FACSDiva software (BD Biosciences). The cerebellum fromMath1-GFP+ mice
was dissected out and manually dissociated in ice-cold dissociation buffer.
Additional details are available in the Supplemental Experimental Procedures.
Mice
Allmouseexperimentswereperformedwith theapproval of theUniversite´ Libre
de Bruxelles Committee for animal welfare. The Bcl6+/mice, in which the null
allele lacked exons 4–10, were a generous gift from R. Dalla-Favera (Columbia
University) (Ye et al., 1997). The tet-o-BCL6 mice, in which human BCL6
expression was under the control of the tetracycline-responsive minimal pro-
moter (20 copies), were a generous gift from B. Baron (University of Chicago)
(Baron et al., 2004). The Bcl6lox/lox mice, in which the exons 7–9 of the Bcl6
gene were flanked by loxP sites, were a generous gift from T. Takemori (RIKEN
Research Center for Allergy and Immunology) (Kaji et al., 2012). Math1-GFP
knockin mice (013593), Math1-creERT2 (007684), SmoM2 (005130), Rosa26-
rtTA (006965), and Trp53lox/lox (008462) were purchased from The Jackson
Laboratory. For EdU labeling, P7 mice were injected intraperitoneally (i.p.)
with a single pulse (50 mg/kg of body weight) of EdU and killed after 24 hr.
Tamoxifen (Sigma-Aldrich) was dissolved in warm corn oil (Sigma-Aldrich)
and stored at 20C. For conditional deletion of Bcl6 and Trp53, pregnant
females were i.p. injected with tamoxifen (0.5 mg) at E15.5. For induction of
SmoM2 expression, P4 pups were i.p. injected with tamoxifen (0.25 mg).
Doxycyclin (Sigma-Aldrich) was dissolved in water and stored at 20C. For
BCL6 transgene expression, P4micewere i.p. injectedwithdoxycyclin (0.5mg).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2014.10.021.
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